EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial

Yasushi Ishigaki iD, Masamichi Yamada, Tomotaka Shingaki iD, Tomonori Oura, Iichiro Shimomura

Obesity · 2026

DOI: 10.1002/oby.70131 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Obesity, 2026. Verfasst von Yasushi Ishigaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Tirzepatide. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight.

Methods

Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m 2 or ≥ 27 kg/m 2 and ≥ 1 weight‐related comorbidity were analyzed. Coprimary endpoints were mean percent change in body weight and the proportion of participants who achieved ≥ 5% body weight reduction at week 72.

Results

Participants in the tirzepatide 5‐, 10‐, and 15‐mg groups had a statistically significantly greater (all p < 0.001) least squares mean (standard error) percent change in body weight compared with those in the placebo group: −12.0% (1.7%), −22.4% (1.7%), −22.1% (1.6%), and −0.3% (1.6%), respectively. Overall, 91.7%, 100%, and 96.6% of participants in the tirzepatide 5‐, 10‐, and 15‐mg groups, respectively, had ≥ 5% weight reduction at week 72, compared with 15.4% in the placebo group. Significant improvements in cardiometabolic measures were also observed with tirzepatide at week 72 compared to placebo. No new safety concerns were identified.

Conclusions

Once‐weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo in Japanese adults with obesity or overweight. Trial Registration ClinicalTrials.gov identifier: NCT04184622 https://clinicaltrials.gov/study/NCT04184622

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityTirzepatideAdultFemaleHumansMaleMiddle AgedBody Mass IndexDouble-Blind MethodJapanOverweightTreatment OutcomeWeight LossEast Asian People

Stichwörter der Autor:innen

Japanobesityoverweighttirzepatide

Substanzen

Anti-Obesity AgentsTirzepatide

Autor:innen und Institutionen

  • Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
  • Tokyo Center Clinic, Tokyo, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Hyogo, Japan.
  • Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

ORCID-Profile: Yasushi Ishigaki, Tomotaka Shingaki

Förderung

  • Eli Lilly and Company

Zitieren

APA

Ishigaki, Y., Yamada, M., Shingaki, T., Oura, T., & Shimomura, I. (2026). Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial. Obesity. https://doi.org/10.1002/oby.70131

Vancouver

Ishigaki Y, Yamada M, Shingaki T, Oura T, Shimomura I. Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial. Obesity. 2026. doi:10.1002/oby.70131

BibTeX
@article{Ishigaki2026,
  author = {Ishigaki, Yasushi and Yamada, Masamichi and Shingaki, Tomotaka and Oura, Tomonori and Shimomura, Iichiro},
  title = {Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70131}
}
Kostenlos starten →